Comparative evaluation of involved free light chain and monoclonal spike as markers for progression from monoclonal gammopathy of undetermined significance to multiple myeloma-Reference-Cited by-同舟云学术

Comparative evaluation of involved free light chain and monoclonal spike as markers for progression from monoclonal gammopathy of undetermined significance to multiple myeloma

Published:2020-09-29 Issue:1 Volume:96 Page:23-30
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Gran Charlotte¹²^ORCID,Liwing Johan¹,Wagner Arnika Kathleen¹,Verhoek Andre³,Gezin Ana³,Alici Evren¹⁴,Nahi Hareth¹⁴

Affiliation:

1. Department of Medicine Karolinska Institutet Stockholm Sweden

2. Department of Clinical Chemistry Karolinska University Laboratory Stockholm Sweden

3. Ingress‐Health Nederland BV Rotterdam The Netherlands

4. Haematology Center Karolinska University Hospital Stockholm Sweden

Funder

Cancerfonden

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.25999

Reference22 articles.

1. Prevalence of Monoclonal Gammopathy of Undetermined Significance

2. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

3. A monoclonal gammopathy precedes multiple myeloma in most patients

4. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study

5. A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of 2 Free Light Chain Assays: Performance of the Free Light Chain Ratio as a Risk Factor for MGUS Progression;Clinical Chemistry;2024-08-29

2. Immune profiles to predict bortezomib-based treatment response for multiple myeloma patients;International Immunopharmacology;2024-03

3. Monoclonal gammopathy of increasing significance: time to screen?;Haematologica;2022-11-10

4. Monoclonal Gammopathies of Clinical Significance: A Critical Appraisal;Cancers;2022-10-26